Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN versus MYCELEX 7 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN versus MYCELEX 7 COMBINATION PACK.
GRISEOFULVIN vs MYCELEX-7 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubular protein tubulin, disrupting mitotic spindle formation and inhibiting fungal cell mitosis. Also interferes with fungal nucleic acid synthesis and cell wall deposition.
Clotrimazole, an imidazole antifungal, inhibits cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis in fungal cell membranes, increasing membrane permeability and causing cell death. Miconazole, also an imidazole, similarly inhibits CYP51, disrupting ergosterol synthesis.
500 mg orally once daily or 250 mg orally twice daily; microsize formulation: 500-1000 mg orally once daily; ultramicrosize formulation: 330-375 mg orally once daily. Administer with fatty meal to enhance absorption.
Clotrimazole vaginal cream 1%: one applicatorful (approximately 5 g) intravaginally at bedtime for 7 consecutive days. Clotrimazole vaginal tablets 100 mg: one tablet intravaginally at bedtime for 7 consecutive days.
None Documented
None Documented
Clinical Note
moderateGriseofulvin + Estrone sulfate
"The metabolism of Estrone sulfate can be increased when combined with Griseofulvin."
Clinical Note
moderateGriseofulvin + Tranilast
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast."
Clinical Note
moderateGriseofulvin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tolfenamic acid."
Clinical Note
moderateGriseofulvin + Nimesulide
Terminal elimination half-life is 9 to 24 hours; clinically, it allows once or twice daily dosing.
Topical clotrimazole has a terminal elimination half-life of 3-6 hours; systemic absorption is minimal, so half-life is not clinically relevant for local effects.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; metabolites excreted in urine (approximately 50%) and feces (approximately 36%) within 24 hours.
Clotrimazole is primarily excreted via feces (approximately 65%) as metabolites and unchanged drug; renal excretion accounts for less than 1% after topical administration. Biliary excretion is negligible.
Category D/X
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide."